GlassScriptPhysician profile
Gordon Auyeung
NPI 1043741291
$2,097.56
in general payments reported to CMS, 2019-2025
21 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.14 · 2020: $189 · 2021: $539 · 2022: $274 · 2023: $207 · 2024: $256 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.68 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337.13 | 2020-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $244.70 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $197.52 | 2021-2023 | |
| Pfizer INC. | $166.84 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.87 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $114.12 | 2020-2022 | |
| Biogen, INC. | $113.57 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $110.83 | 2020-2021 | |
| Amgen INC. | $108.01 | 2020-2025 | Repatha, Otezla |
| Abbvie INC. | $82.14 | 2023-2024 | Viberzi, Linzess |
| Esperion Therapeutics, INC. | $76.88 | 2020-2021 | |
| Lilly USA, LLC | $70.64 | 2022-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $60.07 | 2022-2024 | |
| Seqirus USA INC | $53.83 | 2022-2025 | Fluad, Flucelvax |
| Ibsa Pharma INC. | $46.30 | 2023 | Tirosint, Licart |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $37.43 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.01 | 2024 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $28.13 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Genentech USA, INC. | $27.14 | 2019 | |
| Axsome Therapeutics, INC. | $16.00 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $14.40 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Auyeung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.